Amoun Pharmaceutical Company S.A.E.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Amoun Pharmaceutical Company S.A.E.
Bausch Health is paying down its debt with a $630m IPO for its Bausch + Lomb eyecare product business.
With its IPO of Bausch + Lomb bringing in $630m in proceeds, Bausch Health is moving forward with its plan to use the eye care unit’s separation to pay down its remaining debt.
During Bausch Health’s first quarter earnings call, CEO Papa said he’ll lead Bausch + Lomb following the corporate split. Overall the company reported flat revenues, but said its pandemic rebound is ongoing.
Tempest goes public via a reverse merger with Millendo. Takeda inks its ninth deal of 2021, a discovery pact with BridGene around its chemoproteomics technology.
- Generic Drugs
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.